SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-07-28
👔
Scribe Therapeutics, Inc.
@SCTX_InsiderForm 4 Filing: Oakes Benjamin L. Acquires (Grant) shares of $SCTX
STOCK AWARD / GRANT
⚡ MATERIALITY: 2/10
corporate issuer
Scribe Therapeutics, Inc.
Ticker: $SCTX
Transaction Value
N/A (Non-Open-Market)
Price/Share: $0.00 (Non-Open-Market)
transaction date
2026-03-13
Shares: 707,352
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Oakes Benjamin L., holds the title of President, CEO at Scribe Therapeutics, Inc..
On 2026-03-13, the insider transacted 707,352 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.
Executive Summary Summary
Oakes Benjamin L. (President, CEO) was granted $0 of $SCTX
Post-Transaction Position: 12,969 shares
SEC Accession No: 0002127814-26-000004 (CIK: 2127814)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.